688202 Shanghai Medicilon Inc.
- 32.41
- +0.27+0.84%
Shanghai Medicilon Inc. News
Shanghai Medicilon Inc. (688202.SH): Recently, the prices of laboratory monkeys have stabilized.
On December 20, Gelonghui reported that Shanghai Medicilon Inc. (688202.SH) recently stated during an institutional investor research session that the prices of experimental monkeys have stabilized. The company has proactively taken various measures to ensure the stability of its supply of experimental animals, particularly experimental monkeys, by enriching procurement channels and deepening cooperation with suppliers of experimental animals, to meet the needs of its operation.
Shanghai Medicilon Inc. (688202.SH): The company has established a multi-point layout in key overseas industrial regions such as the USA, Europe, and the Asia-Pacific.
Gelonghui, December 20, Shanghai Medicilon Inc. (688202.SH) recently stated during an institutional investor survey that the company is establishing a multi-point layout in major overseas industry core regions such as the USA, Europe, and the Asia-Pacific, strengthening laboratory capabilities and building a business team. Currently, the company has over ten members in its BD team in the USA and will continue to enhance the BD team in the European market, increase communication between overseas BD and domestic research teams, establish a client information intelligence system, ensure effective management of major client services, and gradually build a market sales system that adapts to overseas market competition. In addition, the company will actively participate in overseas industry conferences, increasing the regular engagement of the research team.
Further Weakness as Shanghai Medicilon (SHSE:688202) Drops 8.2% This Week, Taking Three-year Losses to 85%
Is Shanghai Medicilon (SHSE:688202) Weighed On By Its Debt Load?
Medici: Medici: THIRD QUARTER REPORT 2024
Medici: Third quarter report 2024
shanghai medicilon inc. (688202.SH): net loss of 0.129 billion yuan in the first three quarters.
On October 30, shanghai medicilon inc. (688202.SH) announced that the company achieved revenue of 0.802 billion yuan in the first three quarters, a year-on-year decrease of 32.2%; net income attributable to the parent company was -0.129 billion yuan; non-recurring net profit attributable to the parent company was -0.142 billion yuan.
The Market Lifts Shanghai Medicilon Inc. (SHSE:688202) Shares 41% But It Can Do More
shanghai's three major leading industry mother funds have started, catalyzing CRO companies like shanghai medicilon inc. to embrace new opportunities for technological innovation.
Recently, Shanghai Guotou Leading Private Equity Fund Management Company officially launched the selection work for the sub-funds of the three leading industrial parent funds, aiming to enhance the development level of Shanghai's integrated circuits, biomedical, and ai industries, in order to promote the high-quality development of the Shanghai economy. As one of the economic centers of China, Shanghai, with biomedical as an important industry pillar, has nurtured many excellent research institutions and high-level pharmaceutical companies here. The scale of the Shanghai biomedical industry has grown from 103.46 billion yuan in 2008 to 600 billion yuan in 2020, with a compound annual growth rate of 15.8%.
Shanghai Medicilon Inc.'s (SHSE:688202) Market Cap Increased by CN¥767m, Insiders Receive a 46% Cut
Shanghai Medicilon Inc. (688202.SH): In August, the company did not repurchase shares.
On August 31, 2024, Medicilon Inc. (688202.SH) announced that it did not repurchase any shares in August 2024. As of August 31, 2024, the company has repurchased a total of 258,153 shares through the Shanghai Stock Exchange system, accounting for 0.1917% of the total share capital. The highest price at which the shares were repurchased was RMB 32.55 per share, and the lowest price was RMB 26.44 per share. The total amount paid was RMB 7,450,315.99 (excluding stamp duty, transaction fees, and other expenses).
Shanghai Medicilon Inc.: Half-year report for the year 2024.
Shanghai Medicilon Inc.: Summary of Half-Year Report in 2024.
Shanghai Medicilon Inc. (688202.SH): net loss of 70.23 million yuan in the first half of the year, turning losses year-on-year.
On August 19, Gelonhui reported that Shanghai Medicilon Inc. (688202.SH) released its half-year report for 2024. The company's new orders and revenue both declined year-on-year in the first half of 2024. The company achieved revenue of 0.521 billion yuan, a decrease of 40.23% year-on-year. During the reporting period, the company's customer structure was mainly domestic customers, with domestic customer income of 0.331 billion yuan, accounting for 63.66% of the main business income; overseas customer income was 0.189 billion yuan, accounting for 36.34% of the main business income; the net loss was 70.23 million yuan, turning a year-on-year loss. During the reporting period, net income attributable to shareholders of the listed company was not disclosed.
Even With A 27% Surge, Cautious Investors Are Not Rewarding Shanghai Medicilon Inc.'s (SHSE:688202) Performance Completely
Shanghai Medicilon Inc. (688202.SH): Has cumulatively repurchased 0.1917% of the company's shares.
On August 2, Glonhooi reported that up to July 31, 2024, shanghai medicilon inc has repurchased 258,153 shares of the company through the Shanghai Stock Exchange trading system by centralized bidding, accounting for 0.1917% of the total share capital of the company. The highest and lowest repurchase prices were 32.55 yuan/share and 26.44 yuan/share, respectively, and the total amount paid was RMB 7,450,315.99 (excluding transaction costs such as stamp duty and brokerage fees).
Medicilon Y Hengrui Pharma Profundizan La Colaboración Estratégica
Medicilon Et Hengrui Pharma Renforcent Leur Collaboration Stratégique Pour Soutenir L'innovation Dans Les ADC, Les Petits Acides Nucléiques Et Les Médicaments CGT
Shanghai Medicilon (SHSE:688202) Has Debt But No Earnings; Should You Worry?
Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs
No Data